Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Delorme

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Radiology|February 21, 2018
Radiomics Based on Adapted Diffusion Kurtosis Imaging Helps to Clarify Most Mammographic Findings Suspicious for CancerSebastian Bickelhaupt, Paul Ferdinand Jaeger, Frederik Bernd Laun, et al.
Radiology|February 27, 2019
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)Christina Messiou, Jens Hillengass, Stefan Delorme, et al.
Academic Radiology|January 23, 2025
Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRIFabian Bauer, Jessica Kächele, Juliane Bernhard, et al.
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
British Journal of Haematology|April 27, 2011
Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histologyJens Hillengass, Tobias Bäuerle, Reiner Bartl, et al.
Investigative Radiology|September 27, 2022
In Vivo Repeatability and Multiscanner Reproducibility of MRI Radiomics Features in Patients With Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional StudyMarkus Wennmann, Fabian Bauer, André Klein, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Clinical and Translational Science|November 3, 2023
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacyNicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Radiology|February 21, 2018
Radiomics Based on Adapted Diffusion Kurtosis Imaging Helps to Clarify Most Mammographic Findings Suspicious for CancerSebastian Bickelhaupt, Paul Ferdinand Jaeger, Frederik Bernd Laun, et al.
Radiology|February 27, 2019
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)Christina Messiou, Jens Hillengass, Stefan Delorme, et al.
Academic Radiology|January 23, 2025
Advanced Automated Model for Robust Bone Marrow Segmentation in Whole-body MRIFabian Bauer, Jessica Kächele, Juliane Bernhard, et al.
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
British Journal of Haematology|April 27, 2011
Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histologyJens Hillengass, Tobias Bäuerle, Reiner Bartl, et al.
Investigative Radiology|September 27, 2022
In Vivo Repeatability and Multiscanner Reproducibility of MRI Radiomics Features in Patients With Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional StudyMarkus Wennmann, Fabian Bauer, André Klein, et al.
Nature Communications|October 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Clinical and Translational Science|November 3, 2023
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacyNicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Pageof 17